Background -Patients admitted with acute exacerbation of chronic obstructive pulmonary disease (COPD) are often prescribed ipratropium bromide in combination with a P2 agonist such as salbutamol. Studies have not shown any benefit in adding ipratropium bromide to salbutamol in acute exacerbations of COPD, but these studies have only assessed patients for 60-90 minutes and short term studies may not predict long term clinical response. Combination therapy with the two drugs was compared with salbutamol alone in the treatment of acute exacerbations of COPD during a hospital admission. Methods -Seventy patients admitted to hospital with an acute exacerbation of COPD were randomly allocated to receive either nebulised salbutamol 5 mg and ipratropium bromide 500 tg, or nebulised salbutamol 5 mg alone (all four times a day) on admission. All other treatment was prescribed at the discretion of the attending physician. Length ofstay in hospital and spirometeric values on days 1, 3, 7, 14, and discharge were assessed. Patients completed a subjective symptom score each day. Results -There was no difference between the two groups in the mean (SD) length of stay (salbutamol 10-5 (4.7) days, salbutamol + ipratropium bromide 11*8 (4.4) days; 95% CI -1-02 to 3.62). There was no difference in spirometric values on days 1, 3, 7, 14, or discharge between the two groups. The subjective improvement was similar with both treatments. Conclusions -The routine addition of nebulised ipratropium bromide to salbutamol appears to be of no benefit in the treatment of acute exacerbations of COPD. (Thorax 1995;50:834-837) Keywords: chronic obstructive pulmonary disease, P2 agonist, ipratropium bromide.
Abstract
Background -Patients admitted with acute exacerbation of chronic obstructive pulmonary disease (COPD) are often prescribed ipratropium bromide in combination with a P2 agonist such as salbutamol. Studies have not shown any benefit in adding ipratropium bromide to salbutamol in acute exacerbations of COPD, but these studies have only assessed patients for 60-90 minutes and short term studies may not predict long term clinical response. Combination therapy with the two drugs was compared with salbutamol alone in the treatment of acute exacerbations of COPD during a hospital admission. Methods -Seventy patients admitted to hospital with an acute exacerbation of COPD were randomly allocated to receive either nebulised salbutamol 5 mg and ipratropium bromide 500 tg, or nebulised salbutamol 5 mg alone (all four times a day) on admission. All other treatment was prescribed at the discretion of the attending physician. Length ofstay in hospital and spirometeric values on days 1, 3, 7, 14, and discharge were assessed. Patients completed a subjective symptom score each day. Results -There was no difference between the two groups in the mean (SD) length of stay (salbutamol Patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease (COPD) are usually treated with a high dose P2 agonist as part of their therapy. It is now commonplace for patients to receive, in addition, nebulised ipratropium bromide with obvious additional cost. This is logical pharmacologically as ipratropium has a different mode of action, inhibiting vagally-mediated bronchomotor tone.' There is evidence that adding ipratropium bromide to a nebulised 12 agonist is valuable in the long term management of COPD2A and in acute severe asthma.5 There have been no studies, however, on the place of ipratropium bromide in the management of acute exacerbations of COPD. Additionally, it has been known for some years that atropine-like drugs may be more effective in remissions of airways obstruction than in relapse. 67 We have therefore compared nebulised salbutamol with nebulised salbutamol plus ipratropium bromide (combination therapy) in the treatment of acute exacerbations of COPD in a randomised trial.
Methods
Patients admitted as emergencies to acute medical units with a diagnosis of an acute exacerbation of COPD who were not taking regular nebulised bronchodilators at home were eligible for the study. All were aged over 45 years and had a smoking history of more than 10 pack years. All had a forced expiratory volume in one second (FEV,) of <65% predicted when well, and a history of exertional dyspnoea resulting from respiratory disease for over three years. The diagnosis of non-asthmatic COPD was made previously by a consultant respiratory physician. Exclusion criteria included a history suggestive of asthma (childhood respiratory disease, atopy, night time wheezing) and a peripheral eosinophilia of >10%. Patients with a >20% (at least 200 ml) reversibility of FEV, to 400 ptg of inhaled salbutamol on the day of discharge were also excluded.
On admission patients were randomised to receive either nebulised salbutamol 5 mg four times daily or salbutamol 5 mg plus ipratropium bromide 500 ptg four times daily. The drugs were administered by an air driven nebuliser (Bard Inspiron Mini-Neb) at a flow rate of 8 1/min until the chamber was dry. The combination therapy was given as a mixture. All other medication was prescribed at the attending physician's discretion.
Spirometric values (best of three attempts using a Vitalograph dry wedge spirometer by one of two experienced operators) were measured before the 18 .00 hours nebuliser treat- We also thank Dr David Braunholtz for his statistical advice.
